Author

Bruno Bonaz 1

1 Chu Nord Hépato-Gastroentérologie, Gastroenterologie, Grenoble Cede, France

DEVELOPMENT OF A SMALL BOWEL CAPSULE ENDOSCOPIC INDEX OF SEVERITY IN PATIENTS WITH CROHN’S DISEASE

Arnaud Bourreille, Alain Attar, Vincent Maunoury, Marion Simon, Laurence Picon, Mathurin Fumery, Stéphanie Viennot, Catherine Reenaers, Isabelle Nion Larmurier, Jerome Filippi, Bruno Bonaz, Olivier Dewit, Xavier Dray, Jacques Moreau, Romain Altwegg, Xavier Roblin, Carmen Stefanescu, Jean Yves Mary

EFFICACY AND SAFETY OF GRANULOCYTE, MONOCYTE/MACROPHAGE ADSORPTIVE APHERESIS IN STEROID-DEPENDENT ACTIVE UC WITH INSUFFICIENT RESPONSE OR INTOLERANCE TO IMMUNOSUPPRESSANTS AND/OR BIOLOGICAL THERAPIES (THE ART TRIAL): CALPROTECTIN AND ENDOSCOPY RESULTS 

Axel Dignass, Ayesha Akbar, Bruno Bonaz

EFFICACY AND SAFETY OF GRANULOCYTE, MONOCYTE/MACROPHAGE ADSORPTIVE APHERESIS IN STEROID-DEPENDENT ACTIVE UC WITH INSUFFICIENT RESPONSE OR INTOLERANCE TO IMMUNOSUPPRESSANTS AND/OR BIOLOGICAL THERAPIES (THE ART TRIAL): SAFETY RESULTS AT 12 WEEKS

Axel Dignass, Bruno Bonaz, Ayesha Akbar, Raphael Gruber

EXPECTATIONS OF PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS ) : A PROSPECTIVE SURVEY OF THE FRENCH ORGANIZATION OF IBS PATIENTS

Jean-Marc Sabate, Philippe Ducrotté, Thierry PICHE, Frank Zerbib, Michel Dapoigny, Stanislas Bruley des Varannes, Bruno Bonaz, Francois Mion, Franck Iglicki, Didier Denhez, Doryssemma Tchatat, Suzelle Façon, Pauline Jouet

GASTRIC ELECTRICAL STIMULATION (GES) FOR REFRACTORY VOMITING: RESULTS OF A PROSPECTIVE MULTICENTER DOUBLE-BLINDED RANDOMIZED CONTROLLED CROSS-OVER TRIAL

Philippe Ducrotté, Benoit Coffin, Nicolas Mathieu, Sebastien Fontaine, Stanislas Bruley des Varannes, Frank Zerbib, Bernard CAIAZZO, JEAN CHARLES GRIMAUD, Francois Mion, SAMY HADJADJ, Lucine Vuitton, Alain ROPERT, Philippe Pouderoux, Michel Dapoigny, Jean-Marc Sabate, Bruno Bonaz, Guillaume Gourcerol, bruno guerci

GRANULOCYTE, MONOCYTE/MACROPHAGE ADSORPTIVE APHERESIS IN STEROID-DEPENDENT ACTIVE UC WITH INSUFFICIENT RESPONSE OR INTOLERANCE TO IMMUNOSUPPRESSANTS AND/OR BIOLOGICAL THERAPIES (THE ART TRIAL): SAFETY RESULTS AT 48 WEEKS

Axel Dignass, Bruno Bonaz, Ayesha Akbar, Raphael Gruber

Item 1 - 6 / 9
1